Vivos Inc (RDGL)

[familyof5]

$RDGL Timeline: The Road to FDA IDE Approval (Human Clinical Trials)

We have now held 3 of 5 meetings with the FDA in preparation for our next IDE submission for Radiogel. We maintain our targeted submission timeframe

September 20, 2024

Update on the IDE and @RadioGel pic.twitter.com/oise2Cmq5v

— Vivos Inc. (@VivosIncUSA) September 21, 2024

We can confirm that after our (FDA sprint) meeting, we have determined a solid path forward that can be accomplished

September 13, 2024

Update from todays Sprint meeting #vivosincusa #cancer #CancerAwareness $RDGL pic.twitter.com/rfrf0iQjLl

— Vivos Inc. (@VivosIncUSA) September 13, 2024

Five sprint meetings are scheduled over the next 6 weeks beginning Sept. 13

September 6, 2024

August Monthly Update @RadioGel @IsoPetForCancer #Cancer $RDGL pic.twitter.com/ETCDMy9LNM

— Vivos Inc. (@VivosIncUSA) September 6, 2024

The FDA is being very cooperative by actively engaging us in dialog

September 4, 2024

Update from the CEO $RDGL pic.twitter.com/6GozWh5Ijq

— Vivos Inc. (@VivosIncUSA) September 4, 2024

This is our opportunity to demonstrate the safety features of Radiogel for treating solid cancerous tumors in HUMANS

August 30, 2024

End of the month update on our @RadioGel division #Cancer $RDGL pic.twitter.com/M2rNwlWJpk

— Vivos Inc. (@VivosIncUSA) August 30, 2024

Dosimetry: the determination and measurement of the amount or dosage of radiation absorbed by a substance or living organism by means of a dosimeter. Note: Dosimetry is often used to monitor personnel working with radioactive materials or patients receiving radiotherapy. dosimetric. ?do-s?-'me-trik. adjective.

August 16, 2024

Update from the CEO regarding the ongoing discussions with the FDA. General updates will be posted on this platform as new information becomes available. Subscribe to our newsletter at https://t.co/FfgSTxpyrZ for important press releases for #RadioGel and #IsoPet $RDGL pic.twitter.com/1t2fJ1hcnS

— Vivos Inc. (@VivosIncUSA) August 16, 2024

This allows Vivos Inc the opportunity to obtain FDA feedback from the FDA prior to the intended premarket submission (IDE)

July 30, 2024

If you missed our press yesterday please visit our website, https://t.co/FfgSTxp0Cr

We will update on this platform and our website as information becomes available. Thank you for your support during these exciting times. #Cancer #VivosIncUSA @RadioGel $RDGL pic.twitter.com/vxCU5IdBz7

— Vivos Inc. (@VivosIncUSA) July 30, 2024